This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Bernstein Liebhard LLP
Bernstein Liebhard LLP continues to investigate Fosamax lawsuits on behalf of victims of atypical femur fractures allegedly caused by Fosamax.
New York, New York (PRWEB) November 24, 2012
As Fosamax lawsuits continue to move forward, a newly published- study has detailed the serious complications faced by the victims of atypical femur fractures associated with the use of Fosamax and other bisphosphonates. The study, which appeared in the October 2012 issue of The Journal of Clinical Endocrinology & Metabolism, found that bisphosphonate patients who suffer atypical femur fractures while using Fosamax experienced delayed healing, prodromal pain (pain experienced prior to the actual fracture), and persisting risk of a contralateral and/or other fracture. The authors of the study surveyed 81 patients who had been taking bisphosphonates for an average of 9.5 years, most of whom (94%) had been prescribed Fosamax.*
“This study is an important reminder that Fosamax side effects, especially atypical femur fractures, can be extremely painful and debilitating,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of drugs and medical devices. The firm is currently offering free lawsuit evaluations to victims of serious Fosamax side effects, including atypical femur fractures.
Fosamax is an oral bisphosphonate used to prevent fractures in people who have bone weakening diseases like osteoporosis and Paget’s disease. In October 2010, the U.S. Food & Drug Administration (FDA) advised that people taking Fosamax and other bisphosphonates for osteoporosis are at risk of suffering atypical femur fractures.** Just this past May, an FDA-commissioned analysis published in the New England Journal of Medicine found that there was little benefit in taking Fosamax and similar drugs for longer than five years. The report cited serious Fosamax side effects, including femur fractures and ONJ.***
Hundreds of Fosamax lawsuits are currently pending in a consolidated litigation in New Jersey Superior Court, Atlantic County. Plaintiffs allege long-term use of the drug caused users to suffer serious Fosamax side effects, including Fosamax femur fractures and Osteonecrosis of the Jaw (ONJ), a bone-decaying jaw disorder. (In re: Fosamax Litigation, No. 282, N.J. Super. Ct.)
Bernstein Liebhard LLP is actively filing Fosamax lawsuits on behalf of individuals who were allegedly injured as a result of taking Fosamax. If you suffered a femur fracture, you may be entitled to compensation for medical bills, pain and suffering, lost wages and other injuries. A wealth of information regarding Fosamax lawsuits and Fosamax side effects is available by visiting Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/. To arrange for a free case review, please contact Bernstein Liebhard LLP at (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebFosamax-Lawsuits/Fosamax-Femur-Fractures/prweb10160506.htm